Oruka Therapeutics, Inc. ORKA Weighted Average Exercise Price of Vested and Expected to Vest Options
Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s weighted average exercise price of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s weighted average exercise price of vested and expected to vest options?
- Oruka Therapeutics, Inc. (ORKA) reported weighted average exercise price of vested and expected to vest options of $18.66 in Q1 2026.
- How has Oruka Therapeutics, Inc.'s weighted average exercise price of vested and expected to vest options changed year-over-year?
- Oruka Therapeutics, Inc.'s weighted average exercise price of vested and expected to vest options increased by 56.0% year-over-year, from $11.96 to $18.66.
- What does weighted average exercise price of vested and expected to vest options mean?
- This metric represents the average price at which holders of share-based payment awards can purchase company stock for options that are currently vested or expected to vest. It serves as a key indicator of the potential dilution impact and the alignment between employee compensation and shareholder value creation. Investors use this to assess the cost basis of equity incentives relative to the current market price of the company's common stock.